Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
CAM2029
GEP-NET
High bioavailability
High plasma exposure
Octreotide
Randomised active-controlled
SORENTO
Somatostatin receptor ligands
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
16 Jan 2024
16 Jan 2024
Historique:
received:
20
06
2023
accepted:
24
11
2023
medline:
17
1
2024
pubmed:
17
1
2024
entrez:
16
1
2024
Statut:
epublish
Résumé
The current standard of care (SoC) for the initial treatment of unresectable or metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NET) requires initiation of first-generation somatostatin receptor ligand (SRL) therapy, octreotide and lanreotide, which provide safe and efficacious tumour/symptom control in most patients. However, disease progression can occur with SoC SRL treatment and the optimal dose response of SRL remains unknown. Octreotide subcutaneous depot (CAM2029) is a novel, long-acting, high-exposure formulation that has shown greater bioavailability and improved administration than octreotide long-acting release (LAR) with a well-tolerated safety profile. Retrospective data have highlighted a potential benefit of high-exposure SRL for improved disease control in patients who did not adequately respond to the current SoC SRL treatment. This trial will investigate the efficacy and tolerability of CAM2029 compared to the current SoC, including octreotide LAR and lanreotide autogel (ATG). SORENTO is a prospective, multicentre, randomised, active-controlled, open-label phase 3 trial aiming to demonstrate superiority of treatment with 20 mg octreotide subcutaneous depot (CAM2029) every 2 weeks (Q2W) compared to treatment with the Investigator's choice of SRL therapy at standard doses for tumour control (octreotide LAR 30 mg or lanreotide ATG 120 mg every 4 weeks [Q4W]) as assessed by progression-free survival (PFS) in approximately 300 patients with unresectable/metastatic and well-differentiated GEP-NET. Upon confirmation of disease progression (determined by a Blinded Independent Review Committee [BIRC] and defined as per RECIST 1.1), patients may enter an open-label extension treatment period with once weekly dosing, to investigate the effects of higher frequency dosing. Overall survival follow-up will end a maximum of 2 years after primary analysis. The primary endpoint will be analysed after 194 confirmed PFS events. This is the first trial investigating the efficacy of CAM2029 versus SoC SRL therapy using a head-to-head, superiority trial design. It is expected to be the first trial to investigate the efficacy of increased dosing frequency of a high-exposure SRL. A BIRC will limit bias and measurement variability and ensure high-quality efficacy data. Additionally, inclusion of patients with well-differentiated Grade 3 NET may elucidate treatment strategies for this rarely investigated patient population. ClinicalTrials.gov NCT05050942. Registered on 21st September 2021.
Sections du résumé
BACKGROUND
BACKGROUND
The current standard of care (SoC) for the initial treatment of unresectable or metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NET) requires initiation of first-generation somatostatin receptor ligand (SRL) therapy, octreotide and lanreotide, which provide safe and efficacious tumour/symptom control in most patients. However, disease progression can occur with SoC SRL treatment and the optimal dose response of SRL remains unknown. Octreotide subcutaneous depot (CAM2029) is a novel, long-acting, high-exposure formulation that has shown greater bioavailability and improved administration than octreotide long-acting release (LAR) with a well-tolerated safety profile. Retrospective data have highlighted a potential benefit of high-exposure SRL for improved disease control in patients who did not adequately respond to the current SoC SRL treatment. This trial will investigate the efficacy and tolerability of CAM2029 compared to the current SoC, including octreotide LAR and lanreotide autogel (ATG).
METHODS
METHODS
SORENTO is a prospective, multicentre, randomised, active-controlled, open-label phase 3 trial aiming to demonstrate superiority of treatment with 20 mg octreotide subcutaneous depot (CAM2029) every 2 weeks (Q2W) compared to treatment with the Investigator's choice of SRL therapy at standard doses for tumour control (octreotide LAR 30 mg or lanreotide ATG 120 mg every 4 weeks [Q4W]) as assessed by progression-free survival (PFS) in approximately 300 patients with unresectable/metastatic and well-differentiated GEP-NET. Upon confirmation of disease progression (determined by a Blinded Independent Review Committee [BIRC] and defined as per RECIST 1.1), patients may enter an open-label extension treatment period with once weekly dosing, to investigate the effects of higher frequency dosing. Overall survival follow-up will end a maximum of 2 years after primary analysis. The primary endpoint will be analysed after 194 confirmed PFS events.
DISCUSSION
CONCLUSIONS
This is the first trial investigating the efficacy of CAM2029 versus SoC SRL therapy using a head-to-head, superiority trial design. It is expected to be the first trial to investigate the efficacy of increased dosing frequency of a high-exposure SRL. A BIRC will limit bias and measurement variability and ensure high-quality efficacy data. Additionally, inclusion of patients with well-differentiated Grade 3 NET may elucidate treatment strategies for this rarely investigated patient population.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT05050942. Registered on 21st September 2021.
Identifiants
pubmed: 38229199
doi: 10.1186/s13063-023-07834-8
pii: 10.1186/s13063-023-07834-8
doi:
Banques de données
ClinicalTrials.gov
['NCT05050942']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
58Informations de copyright
© 2024. The Author(s).
Références
Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589–97.
doi: 10.1002/cncr.29099
pubmed: 25312765
Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2020;41(2):372–403.
doi: 10.1210/endrev/bnz004
Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: Are there global differences? Curr Oncol Rep. 2021;23(4):43.
doi: 10.1007/s11912-021-01029-7
pubmed: 33719003
pmcid: 8118193
Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–34.
doi: 10.1016/S1470-2045(17)30110-9
pubmed: 28238592
pmcid: 6066284
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.
doi: 10.1001/jamaoncol.2017.0589
pubmed: 28448665
pmcid: 5824320
Scott AT, Howe JR. Management of small bowel neuroendocrine tumors. J Oncol. 2018;14(8):471–82.
Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(7):839–68.
doi: 10.6004/jnccn.2021.0032
pubmed: 34340212
Kim KW, Krajewski KM, Nishino M, Jagannathan JP, Shinagare AB, Tirumani SH, et al. Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging. AJR. 2013;201(4):811–24.
doi: 10.2214/AJR.12.10240
pubmed: 24059370
Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin analogs in clinical practice: a review. Int J Mol Sci. 2020;21(5):1682.
doi: 10.3390/ijms21051682
pubmed: 32121432
pmcid: 7084228
Rinke A, Muller H, Schade-Brittinger C, Klose K-J, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63.
doi: 10.1200/JCO.2009.22.8510
pubmed: 19704057
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. NEJM. 2014;371(3):224–33.
doi: 10.1056/NEJMoa1316158
pubmed: 25014687
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of
doi: 10.1056/NEJMoa1607427
pubmed: 28076709
Chadha MK, Lombardo J, Mashtare T, Wilding GE, Litwin A, Raczyk C, et al. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2009;29(10):4127–30.
pubmed: 19846960
Tiberg F, Roberts J, Cervin C, Johnsson M, Sarp S, Tripathi AP, et al. Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers. Br J Clin Pharmacol. 2015;80(3):460–72.
doi: 10.1111/bcp.12698
pubmed: 26076191
pmcid: 4574831
Chan DL, Ferone D, Albertelli M, Pavlakis N, Segelov E, Singh S. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. Endocrine. 2017;57(3):366–75.
doi: 10.1007/s12020-017-1360-z
pubmed: 28726183
Lamberti GFA, Brighi N, Tafuto S, Ibrahim T, Brizzi MP, Pusceddu S, et al. Nonconventional doses of somatostatin analogs in patients with progressing well-differentiated neuroendocrine tumor. J Clin Endocrinol Metab. 2020;1(1):dgz035.
Pavel M, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. EJC. 2021;157:403–14.
doi: 10.1016/j.ejca.2021.06.056
Pavel M, Borson-Chazot F, Cailleux A, Hörsch D, Lahner H, Pivonello R, et al. Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. Cancer Chemother Pharmacol. 2019;83(2):375–85.
doi: 10.1007/s00280-018-3734-1
pubmed: 30535537
Seo C, Horodniceanu E, Shah R, Goldstein G, Ray D, Bennett B, et al. A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors. Supprt Care Cancer. 2022;30(7):6307–16.
doi: 10.1007/s00520-022-07054-x
ClinicalTrials.gov. A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET. 2022. Available from: https://ClinicalTrials.gov/show/NCT05050942 .
Dhall D, Mertens R, Bresee C, Parakh R, Wang HL, Li M, et al. Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. Hum Pathol. 2012;43(4):489–95.
doi: 10.1016/j.humpath.2011.06.011
pubmed: 21937080
Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017;29:11–6.
doi: 10.1016/j.anndiagpath.2017.04.005
pubmed: 28807335
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–56.
doi: 10.1097/00000421-198212000-00014
pubmed: 7165009
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). EJC. 2009;45(2):228–47.
doi: 10.1016/j.ejca.2008.10.026
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (sf-36): I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.
doi: 10.1097/00005650-199206000-00002
pubmed: 1593914
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. JNCI. 1993;85(5):365–76.
doi: 10.1093/jnci/85.5.365
pubmed: 8433390
Yadegarfar G, Friend L, Jones L, Plum L, Ardill J, Taal B, et al. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Brit J Cancer. 2013;108(2):301–10.
doi: 10.1038/bjc.2012.560
pubmed: 23322194
pmcid: 3566824
Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:1–13.
doi: 10.1186/1477-7525-2-1
Guy W. Clinical global impressions. ECDU assessment manual for psychopharmacology—revised. Rockville, MD: US Department of Health, Education, and Welfare. Public Health Service, Alcohol; 1976. p. 218–22.
Ferolla P, Faggiano A, Grimaldi F, Ferone D, Scarpelli G, Ramundo V, et al. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Invest. 2012;35(3):326–31.
pubmed: 21757992
Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol. 2008;26(22):3791–6.
doi: 10.1200/JCO.2008.16.1711
pubmed: 18669467
pmcid: 2654812
Pellat A, Coriat R. Well differentiated grade 3 neuroendocrine tumors of the digestive tract: A narrative review. J Clin Med. 2020;9(6):1677.
doi: 10.3390/jcm9061677
pubmed: 32492939
pmcid: 7357105
Xu J-X, Wu D-H, Ying L-W, Hu H-G. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification. WJG. 2021;27(47):8123–37.
doi: 10.3748/wjg.v27.i47.8123
pubmed: 35068858
pmcid: 8704278
Izmailova ES, Ellis R, Benko C. Remote monitoring in clinical trials during the COVID-19 pandemic. Clin Transl Sci. 2020;13(5):838–41.
doi: 10.1111/cts.12834
pubmed: 32526077
pmcid: 7307062
Sabesan S, Zalcberg J. Telehealth models could be extended to conducting clinical trials-a teletrial approach. Eur J Cancer Care. 2018;27(2):e12587.
doi: 10.1111/ecc.12587
Klein CG, Cicinnati V, Schmidt H, Ganten T, Scherer MN, Braun F, et al. Compliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: a prospective, observational, multicenter study. Ann Transplant. 2013;18:677–84.
pubmed: 24335787
Sorensen CA, Lisby M, Olesen C, Enemark U, Sorensen SB, de Thurah A. Self-administration of medication: a pragmatic randomized controlled trial of the impact on dispensing errors, perceptions, and satisfaction. Ther Adv Drug Saf. 2020;11:2042098620904616.
pubmed: 32435443
pmcid: 7225786
Ter-Minassian M, Zhang S, Brooks NV, Brais LK, Chan JA, Christiani DC, et al. Association between tumor progression endpoints and overall survival in patients with advanced neuroendocrine tumors. Oncologist. 2017;22(2):165–72.
doi: 10.1634/theoncologist.2016-0175
pubmed: 28179574
pmcid: 5330705
Siegel J, Grinsted L, Liu F, Weber H-J, Englert S, Casey M. Censoring and censoring mechanisms in oncology in light of the estimands framework. arXiv preprint arXiv:220301781. 2022.